I Heard These Medications Give You Cancer. Is That True? Risks of Malignancy with IBD Therapy

Ryan R. Gaffney; Andrew Tinsley

doi:10.1007/978-3-319-14072-8_17

I Heard These Medications Give You Cancer. Is That True? Risks of Malignancy with IBD Therapy

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

“Thiopurines (azathioprine and mercaptopurine) and biologic anti-TNF agents (infliximab, adalimumab, certolizumab, and golimumab) are some of the most effective medications that we have for treating inflammatory bowel disease. However, it is important to recognize that these therapies have been associated with an increase in the risk of developing certain cancers including lymphoma and skin cancer. Fortunately, the total number of people who develop these cancers while on therapy is very small. There is also little evidence that thiopurines and anti-TNF drugs significantly increase the risk of other types of cancers. Before initiating treatment with these types of medications, we need to review your cancer risks and weigh them against the considerable benefits these therapies can offer.”

Original language	English (US)
Title of host publication	Inflammatory Bowel Disease
Subtitle of host publication	A Point of Care Clinical Guide
Publisher	Springer International Publishing
Pages	135-140
Number of pages	6
ISBN (Electronic)	9783319140728
ISBN (Print)	9783319140711
DOIs	https://doi.org/10.1007/978-3-319-14072-8_17
State	Published - Jan 1 2015

All Science Journal Classification (ASJC) codes

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-319-14072-8_17

Cite this

@inbook{1496ea6c22a547469182b27a0fd63757,

title = "I Heard These Medications Give You Cancer. Is That True? Risks of Malignancy with IBD Therapy",

abstract = "“Thiopurines (azathioprine and mercaptopurine) and biologic anti-TNF agents (infliximab, adalimumab, certolizumab, and golimumab) are some of the most effective medications that we have for treating inflammatory bowel disease. However, it is important to recognize that these therapies have been associated with an increase in the risk of developing certain cancers including lymphoma and skin cancer. Fortunately, the total number of people who develop these cancers while on therapy is very small. There is also little evidence that thiopurines and anti-TNF drugs significantly increase the risk of other types of cancers. Before initiating treatment with these types of medications, we need to review your cancer risks and weigh them against the considerable benefits these therapies can offer.”",

author = "Gaffney, \{Ryan R.\} and Andrew Tinsley",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-14072-8\_17",

language = "English (US)",

isbn = "9783319140711",

pages = "135--140",

booktitle = "Inflammatory Bowel Disease",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - I Heard These Medications Give You Cancer. Is That True? Risks of Malignancy with IBD Therapy

AU - Gaffney, Ryan R.

AU - Tinsley, Andrew

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2015.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - “Thiopurines (azathioprine and mercaptopurine) and biologic anti-TNF agents (infliximab, adalimumab, certolizumab, and golimumab) are some of the most effective medications that we have for treating inflammatory bowel disease. However, it is important to recognize that these therapies have been associated with an increase in the risk of developing certain cancers including lymphoma and skin cancer. Fortunately, the total number of people who develop these cancers while on therapy is very small. There is also little evidence that thiopurines and anti-TNF drugs significantly increase the risk of other types of cancers. Before initiating treatment with these types of medications, we need to review your cancer risks and weigh them against the considerable benefits these therapies can offer.”

AB - “Thiopurines (azathioprine and mercaptopurine) and biologic anti-TNF agents (infliximab, adalimumab, certolizumab, and golimumab) are some of the most effective medications that we have for treating inflammatory bowel disease. However, it is important to recognize that these therapies have been associated with an increase in the risk of developing certain cancers including lymphoma and skin cancer. Fortunately, the total number of people who develop these cancers while on therapy is very small. There is also little evidence that thiopurines and anti-TNF drugs significantly increase the risk of other types of cancers. Before initiating treatment with these types of medications, we need to review your cancer risks and weigh them against the considerable benefits these therapies can offer.”

UR - https://www.scopus.com/pages/publications/105018276614

UR - https://www.scopus.com/inward/citedby.url?scp=105018276614&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-14072-8_17

DO - 10.1007/978-3-319-14072-8_17

M3 - Chapter

AN - SCOPUS:105018276614

SN - 9783319140711

SP - 135

EP - 140

BT - Inflammatory Bowel Disease

PB - Springer International Publishing

ER -

I Heard These Medications Give You Cancer. Is That True? Risks of Malignancy with IBD Therapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this